Physician profile
Spencer Carter
NPI 1740676238
$57,024.14
in general payments reported to CMS, 2019-2025
15 companies · $1,617 in 2025
The $1,617 reported for 2025 was more than what 80% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $38K · 2021: $10K · 2022: $502 · 2023: $656 · 2024: $6,385 · 2025: $1,617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Food and Beverage: $1,575 · Consulting Fee: $1,500 · Travel and Lodging: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Food and Beverage | $1,575.27 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $1,082.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $32,139.09 | 2019-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic Vascular, INC. | $15,000.00 | 2020 | |
| Pfizer INC. | $6,268.22 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $1,452.27 | 2024 | |
| Medtronic, INC. | $1,136.07 | 2021 | |
| Alnylam Pharmaceuticals INC. | $164.84 | 2024 | Amvuttra |
| Cvrx, INC. | $163.42 | 2023 | Barostim Neo System |
| Penumbra, INC. | $160.53 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $127.50 | 2023 | Wainua |
| Recor Medical INC | $116.68 | 2025 | Paradise Ultrasound Renal Denervation System |
| Angiodynamics, INC. | $102.07 | 2023 | Angiovac |
| Biotronik INC. | $98.41 | 2022 | |
| Cardiovascular Systems INC. | $68.04 | 2019 | |
| Amgen INC. | $27.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.